Emily Bodnar

H.C. Wainwright & Co.

Recent Articles about Jasper Therapeutics Inc.

Biotech Co. Still a Buy Despite Manufacturing Setbacks 07/07/2025

While it received a lower price target due to manufacturing setbacks, Jasper Therapeutics Inc. (JSPR:NASDAQ) is still a Buy, according to an H.C. Wainwright & Co. research note.